Relmada Therapeutics, Inc.
NASDAQ:RLMD
3.26 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Relmada Therapeutics, Inc. |
Symbool | RLMD |
Munteenheid | USD |
Prijs | 3.26 |
Beurswaarde | 98,367,892 |
Dividendpercentage | 0% |
52-weken bereik | 1.88 - 7.223 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Sergio Traversa M.B.A., MBA, Pharm.D., PharmD |
Website | https://www.relmada.com |
An error occurred while fetching data.
Over Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)